AC
GBT

Aaron Cowen’s Global Blood Therapeutics, Inc. GBT Stock Holding History

Aaron Cowen’s Portfolio GBT Stock Details GBT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-21,600
Closed -$1.1M – 105
2020
Q1 		$1.1M Buy
+21,600
New +$1.45M 0.03% 47

Other funds holding GBT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Aaron Cowen's GBT Position: Q2 2020 in Review

Aaron Cowen sold out of Global Blood Therapeutics, Inc. (GBT) in Q2 2020, closing a stake of 21,600 shares — an estimated $1.1M sold.

Aaron Cowen first reported a position in GBT in Q1 2020 and held it in 1 quarter. The position peaked at $1.1M in Q1 2020. 253 funds tracked by Wall St. Rank hold GBT as of Q2 2020.

  • Aaron Cowen reported no remaining Global Blood Therapeutics, Inc. position as of Q2 2020 after selling out during the quarter.
  • Aaron Cowen sold 21,600 Global Blood Therapeutics, Inc. shares in Q2 2020, an estimated $1.1M.
  • Aaron Cowen first reported a position in Global Blood Therapeutics, Inc. in Q1 2020 and held it in 1 quarter.
  • Aaron Cowen's Global Blood Therapeutics, Inc. position peaked at $1.1M in Q1 2020.
  • 253 funds tracked by Wall St. Rank held Global Blood Therapeutics, Inc. as of Q2 2020.

Based on Suvretta Capital Management's 13F filing for Q2 2020, filed 14 Aug 2020.